A first-time pill for endometriosis has been approved for the use of NHS, offering hope for people suffering from weak conditions in England.
Combination drug, Relugolix-Estradiol-Norethisterone (also known as Relugolix combination therapy or ryeqo), is the first long-term daily pellet licensed to treat endometriosis.
It marks a significant advancement on current treatments, providing more convenient and potentially less difficult experience for patients.
The tablet is expected to help about 1,000 endometriosis patients every year.
It works by blocking specific hormones that contribute to endometriosis, providing the required hormone replacement simultaneously. This dual action addresses the root cause of the situation, reducing potential side effects.
Unlike existing injectable remedies, which can initially increase symptoms, ryco can be taken at home, provides rapid relief, and adds multiple hormones to the same pill. This ends the requirement of continuous clinic trips.
Endometriosis occurs when the tissue similar to the womb grows elsewhere in the body, usually in the pelvis, bladder and bowel.
This condition can cause weak pain, heavy duration, exhaustion and reproductive problems, which can greatly affect the personal and business life of women.
According to the National Institute for Health and Care Excellence (NICE), which approved the drug, about 1.5 million people in the UK suffer from endometriosis.
However, it takes nine years if symptoms usually appear to receive a diagnosis. According to the NHS website, this is because symptoms may be similar to people associated with other conditions, such as fibroids, pelvic inflammatory diseases and irritable bowel syndrome.
Nees initially rejected the drug, but the new evidence was provided by the manufacturer Gedon Richter to solve the effectiveness and value for money.
The drug will only be made available to patients on NHS whose medical or surgical treatment has failed for endometriosis.
Helen Knight, director of the Medicine Evaluation at NIS, said: “This new treatment marks a possible phase-change that how we manage endometriosis, ensuring the value for the taxpayer, puts back control in the hands of patients.
“Instead of traveling clinics for injections, there is now a daily tablet that can be taken at home.
“Treatment can also be prevented and can be started more easily, especially important for those who are planning to have children and manage the side effects.
“This feature not only benefits patients, but also reduces pressure on NHS services.”
The list price for treatment is £ 72 for 28-day supply (except VAT).
